Image Place holder

Andrii Monastyrskyi, PhD

Program: Drug Discovery

View Lab Page


    The Monastyrskyi lab harnesses the power of organic chemistry and chemical biology to develop new tools for studying the function and therapeutic potential of cancer targets.          


    • Drug Discovery
    • Breast Oncology
    • Neuro-Oncology
    • Molecular Medicine Program
    • Molecular Medicine Program

Education & Training


  • University of South Florida, PhD - Organic Chemistry


  • The Scripps Research Institute, Fellow - Chemistry

  Our laboratory uses the tools of synthetic organic chemistry, medicinal chemistry, and chemical biology to further develop small molecules for studying and modulating therapeutically relevant cancer targets. One aspect of current work focuses on the development of IND safety assessment candidates that inhibit the transcriptional kinases CDK12 and CDK13, the Wnt/beta-catenin regulators CK1d and CK1e, and the autophagy kinase ULK1. Further, developmental projects in the laboratory include campaigns to develop small molecules that disrupt key protein-protein interactions (e.g., those of Myc and Max) and RNA biogenesis.    


  • Liao Y, Chin Chan S, Welsh EA, Fang B, Sun L, Schönbrunn E, Koomen JM, Duckett DR, Haura EB, Monastyrskyi A, Rix U. Chemical Proteomics with Novel Fully Functionalized Fragments and Stringent Target Prioritization Identifies the Glutathione-Dependent Isomerase GSTZ1 as a Lung Cancer Target. Acs Chem Biol. 2023 Feb.18(2):251-264. Pubmedid: 36630201.
  • Monastyrskyi A, Brockmeyer F, LaCrue AN, Zhao Y, Maher SP, Maignan JR, Padin-Irizarry V, Sakhno YI, Parvatkar PT, Asakawa AH, Huang L, Casandra D, Mashkouri S, Kyle DE, Manetsch R. Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1H)-Quinolones with Single Dose Cures. J Med Chem. 2021 May.64(10):6581-6595. Pubmedid: 33979164. Pmcid: PMC8904075.
  • Tadesse S, Duckett DR, Monastyrskyi A. The promise and current status of CDK12/13 inhibition for the treatment of cancer. Future Med Chem. 2021 Jan.13(2):117-141. Pubmedid: 33295810.
  • Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, Pinilla-Ibarz J. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv. 2020 Jul.4(13):3072-3084. Pubmedid: 32634240. Pmcid: PMC7362385.
  • Vena F, Bayle S, Nieto A, Quereda V, Aceti M, Frydman SM, Sansil SS, Grant W, Monastyrskyi A, McDonald P, Roush WR, Teng M, Duckett D. Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase. Mol Cancer Ther. 2020 Aug.19(8):1623-1635. Pubmedid: 32430484. Pmcid: PMC7415672.
  • Quereda V, Bayle S, Vena F, Frydman SM, Monastyrskyi A, Roush WR, Duckett DR. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer. Cancer Cell. 2019 Nov.36(5):545-558.e7. Pubmedid: 31668947.
  • Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W. Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer. Bioorg Med Chem. 2018 Feb.26(3):590-602. Pubmedid: 29289448. Pmcid: PMC5803353.
  • Monastyrskyi A, Bayle S, Quereda V, Grant W, Cameron M, Duckett D, Roush W. Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors. Bioorg Med Chem Lett. 2018 Feb.28(3):400-404. Pubmedid: 29277458. Pmcid: PMC5999544.
  • Neelarapu R, Maignan JR, Lichorowic CL, Monastyrskyi A, Mutka TS, LaCrue AN, Blake LD, Casandra D, Mashkouri S, Burrows JN, Willis PA, Kyle DE, Manetsch R. Design and Synthesis of Orally Bioavailable Piperazine Substituted 4(1H)-Quinolones with Potent Antimalarial Activity: Structure-Activity and Structure-Property Relationship Studies. J Med Chem. 2018 Feb.61(4):1450-1473. Pubmedid: 29215279. Pmcid: PMC6610884.
  • Monastyrskyi A, Namelikonda NK, Manetsch R. Metal-free arylation of ethyl acetoacetate with hypervalent diaryliodonium salts: an immediate access to diverse 3-aryl-4(1H)-quinolones. J Org Chem. 2015 Mar.80(5):2513-2520. Pubmedid: 25558982. Pmcid: PMC4479256.
  • Monastyrskyi A, Kyle DE, Manetsch R. 4(1H)-pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities. Curr Top Med Chem. 2014 Sep.14(14):1693-1705. Pubmedid: 25116582. Pmcid: PMC4479281.
  • Cross RM, Flanigan DL, Monastyrskyi A, LaCrue AN, Sáenz FE, Maignan JR, Mutka TS, White KL, Shackleford DM, Bathurst I, Fronczek FR, Wojtas L, Guida WC, Charman SA, Burrows JN, Kyle DE, Manetsch R. Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. J Med Chem. 2014 Nov.57(21):8860-8879. Pubmedid: 25148516. Pmcid: PMC4234439.
  • Lacrue AN, Sáenz FE, Cross RM, Udenze KO, Monastyrskyi A, Stein S, Mutka TS, Manetsch R, Kyle DE. 4(1H)-Quinolones with liver stage activity against Plasmodium berghei. Antimicrob Agents Chemother. 2013 Jan.57(1):417-424. Pubmedid: 23129047. Pmcid: PMC3535941.
  • Cross RM, Monastyrskyi A, Mutka TS, Burrows JN, Kyle DE, Manetsch R. Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem. 2010 Oct.53(19):7076-7094. Pubmedid: 20828199.


  • Title: Integrated Fragment-Based Phenotypic Screening and Chemoproteomics for Identification of Novel Small Cell Lung Cancer-Specific Targets
    Sponsor: Nat Institutes of Health
    PI (Contact): Rix, U., PI (MPI): Monastyrskyi, A.
  • Title: Development of first-in-class allosteric covalent inhibitors of CDK11 for the treatment ofrefractory melanoma
    Sponsor: Moffitt Cancer Center
    PI: Monastyrskyi, A., CO-PI: Eroglu, Z.
  • Title: Developing CDK12 inhibitors to overcome therapy resistance in HER2+ and KRAS driven breast and lung cancers
    Sponsor: Nat Institutes of Health
    PI (Contact): Duckett, D., PI (MPI): Monastyrskyi, A., PI (MPI): Haura, E.
  • Title: Harnessing CDK12 inhibition for the treatment of HER2+ brain metastatic breast cancers’
    Sponsor: US Army
    PI: Monastyrskyi, A.